Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Blinded, Randomized and Gardasil-controlled Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

NCT05668572 is registered in ClinicalTrials.gov with Beijing Health Guard Biotechnology, Inc as lead sponsor.

NCT NCT05668572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05668572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Blinded, Randomized and Gardasil-controlled Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
Lead sponsor
Beijing Health Guard Biotechnology, Inc
Phase
Phase 3
Overall status
Unknown status
Start date
December 5, 2020
Completion date
February 23, 2023
Enrollment
12,000 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection